Surrozen, Inc. (NASDAQ:SRZN) Short Interest Up 33.9% in December

Surrozen, Inc. (NASDAQ:SRZN) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 45,400 shares, a growth of 33.9% from the November 30th total of 33,900 shares. Based on an average trading volume of 33,200 shares, the short-interest ratio is presently 1.4 days. Approximately 1.9% of the shares of the company are short sold.

Institutional Trading of Surrozen

A number of institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC bought a new stake in shares of Surrozen during the second quarter valued at about $2,080,000. CVI Holdings LLC purchased a new position in Surrozen during the second quarter valued at approximately $711,000. Nantahala Capital Management LLC bought a new stake in Surrozen during the 2nd quarter worth approximately $2,050,000. Finally, Stonepine Capital Management LLC bought a new position in Surrozen in the 2nd quarter valued at $724,000. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Surrozen Stock Performance

Shares of SRZN stock traded down $0.88 during trading on Friday, reaching $13.90. 48,850 shares of the company’s stock traded hands, compared to its average volume of 18,479. The firm’s 50-day moving average is $10.44 and its 200 day moving average is $9.77. Surrozen has a 1 year low of $6.00 and a 1 year high of $16.19.

Surrozen (NASDAQ:SRZN) last posted its earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.77) by $2.33. The company had revenue of $10.00 million for the quarter. On average, sell-side analysts anticipate that Surrozen will post -7.16 earnings per share for the current year.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.